CSH guidelines for the diagnosis and treatment of drug-induced liver injury

被引：4

作者：

Yue-cheng Yu

Yi-min Mao

Cheng-wei Chen

Jin-jun Chen

Jun Chen

Wen-ming Cong

Yang Ding

Zhong-ping Duan

Qing-chun Fu

Xiao-yan Guo

Peng Hu

Xi-qi Hu

Ji-dong Jia

Rong-tao Lai

Dong-liang Li

Ying-xia Liu

Lun-gen Lu

Shi-wu Ma

Xiong Ma

Yue-min Nan

Hong Ren

Tao Shen

Hao Wang

Ji-yao Wang

Tai-ling Wang

Xiao-jin Wang

Lai Wei

Qing Xie

Wen Xie

Chang-qing Yang

Dong-liang Yang

Yan-yan Yu

Min-de Zeng

Li Zhang

Xin-yan Zhao

Hui Zhuang

机构：

[1] Nanjing University of Chinese Medicine,Liver Disease Center of PLA, Bayi Hospital

[2] Shanghai Jiaotong University,Department of Gastroenterology, Renji Hospital, School of Medicine

[3] Nanjing Military Command,Shanghai Liver Diseases Research Center, 85th Hospital

[4] Southern Medical University,Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital

[5] Central South University,Liver Diseases Center, Second Xiangya Hospital

[6] Second Military Medical University,Department of Pathology, Eastern Hepatobiliary Surgery Hospital

[7] Shengjing Hospital of China Medical University,Department of Infectious Disease

[8] Capital Medical University,Artificial Liver Center, Beijing Youan Hospital

[9] Xi’an Jiaotong University,Department of Gastroenterology, Second Affiliated Hospital

[10] Chongqing Medical University,Department of Infectious Diseases, Institute for Viral Hepatitis, Second Affiliated Hospital

[11] Fudan University,Department of Pathology, School of Medicine

[12] Capital Medial University,Liver Research Center, Beijing Friendship Hospital

[13] Shanghai Jiaotong University,Department of Infectious Diseases, Ruijin Hospital, School of Medicine

[14] Fuzhou General Hospital of PLA,Department of Hepatobiliary Disease

[15] Shenzhen Third People’s Hospital,Department of Liver Disease

[16] Shanghai Jiaotong University,Department of Gastroenterology, Shanghai First People’s Hospital, School of Medicine

[17] Kunming General Hospital of PLA,Department of Infectious Diseases

[18] Hebei Medical University,Department of Traditional and Western Medical Hepatology, Third Affiliated Hospital

[19] Beijing University,Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences

[20] Beijing University,Institute of Hepatology, People’s Hospital

[21] Fudan University,Department of Gastroenterology, Zhongshan Hospital, School of Medicine

[22] Capital Medical University,Department of Pathology, China

[23] Capital Medical University,Japan Friendship Hospital

[24] Tongji University,Center of Liver Diseases, Beijing Ditan Hospital

[25] Huazhong University of Science and Technology,Department of Gastroenterology, Tongji Hospital, School of Medicine

[26] Beijing University First Hospital,Department of Infectious Disease, Union Hospital, Tongji Medical College

[27] Beijing University of Chinese Medicine,Department of Infectious Disease

来源：

Hepatology International | 2017年 / 11卷

关键词：

Drug-induced liver injury; Epidemiology; Pathogenesis; Pathology; Clinical type; Diagnosis; Differential diagnosis; Treatment; Prevention; Recommendations;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into hepatocellular injury, cholestatic injury, hepatocellular-cholestatic mixed injury, and vascular injury based on the types of injured target cells. The CSH guidelines summarized the epidemiology, pathogenesis, pathology, and clinical manifestation and gives 16 evidence-based recommendations on diagnosis, differential diagnosis, treatment, and prevention of DILI.

引用

页码：221 / 241

页数：20

共 304 条

[1]

Björnsson ES(2013)Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland Gastroenterology 144 1419-1425

[2]

Bergmann OM(2009)Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct Drug Saf 32 55-68

[3]

Björnsson HK(2014)ACG Clinical Guide: the diagnosis and management of idiosyncratic drug-induced liver injury Am J Gastroenterol 109 950-966

[4]

Fontana RJ(2012)An update on drug—induced liver injury J Clin Exp Hepatol 2 247-259

[5]

Watkins PB(2016)Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury Am J Gastroenterol 111 958-965

[6]

Bonkovsky HL(2008)Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States Gastroenterology 135 1924-1934

[7]

Chalasani NP(2010)Drug-induced acute liver failure: results of a U.S. multicenter, prospective study Hepatology 52 2065-2076

[8]

Hayashi PH(2012)Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis Pharmacoepidemiol Drug Saf 21 1139-1154

[9]

Bonkovsky HL(2007)Clinical analysis of 275 cases of acute drug-induced liver disease Front Med China 1 58-61

[10]

Devarbhavi H(2013)LiverTox: a website on drug-induced liver injury Hepatology 57 873-874

← 1 2 3 4 5 6 7 8 9 10 →